1. Scrip
  2. >>Business
  3. >>Strategy

Teva/Sanofi’s Phase IIb Data In IBD Look Competitive Vs. Merck, Roche

 
• By Joseph Haas

Teva reported Phase IIb data for its anti-TL1A agent in ulcerative colitis and Crohn’s that the company called transformational and analysts deemed potentially best in class.

Teva logo outside building
Teva reported strong Phase IIb data for its anti-TL1A agent in IBD indications • Source: Shutterstock

Teva and Sanofi unveiled positive Phase IIb data on 17 December for the TL1A-targeting antibody candidate they are developing to compete against candidates from the same class at Roche and Merck & Co. in inflammatory bowel disease (IBD). On a same-day call, Teva execs asserted that their drug, duvakitug (TEV‘574/SAR447189), has produced “transformational” data in both ulcerative colitis and Crohn’s disease as the partners look ahead to planning a Phase III program.

Key Takeaways
  • Teva reported that the TL1A-targeting antibody it is developing for IBD with Sanofi hit primary endpoints in ulcerative colitis and Crohn’s in a Phase IIb trial.
  • The companies now plan to move duvakitug into Phase III, where it will attempt to catch up to Merck & Co.’s tulisokibart and Roche’s RVT-3101, both already in Phase III

In the RELIEVE UCCD study, duvakitug met the primary endpoint of clinical remission in UC with both doses tested, 450mg and 900mg given subcutaneously every two weeks for 14 weeks

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.

How Much Does Biopharma Contribute To The US Economy?

 
• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

More from Therapy Areas

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.